690 results on '"Forconi, Francesco"'
Search Results
2. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
3. High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
4. Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment
5. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia
6. Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells
7. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL
8. DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity
9. Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia
10. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
11. PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
12. S142: FOXO1-RICTOR AXIS INDUCES ADAPTIVE INCREASE IN AKT ACTIVITY DURING BCR INHIBITOR THERAPY IN CLL: IMPLICATIONS FOR COMBINATION THERAPY
13. PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
14. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
15. Development of DNA vaccines against B-cell neoplasms
16. Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL
17. IL-4 enhances expression and function of surface IgM in CLL cells
18. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation
19. Perturbation of the normal immune system in patients with CLL
20. The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model
21. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features
22. MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study
23. Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study
24. DC-SIGN Binding to the Oligomannose-Type Glycans on the Surface Immunoglobulin Variable Region of Follicular Lymphoma Promotes Selective Adhesion to Microenvironmental VCAM-1
25. EMT-like Activation in CLL Provides Novel Therapeutic Target
26. Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK
27. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
28. Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function
29. TP53 Mutations Identified Using NGS Comprise the Overwhelming Majority of TP53 Disruptions in CLL: Results From a Multicentre Study
30. Biological and clinical insight from analysis of the tumor B-cell 2 receptor structure and function in chronic lymphocytic Leukemia
31. S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis
32. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia
33. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia
34. B-cell receptor dependent phagocytosis and presentation of particulate antigen by chronic lymphocytic leukemia cells
35. Biological and Clinical Insight from Analysis of the Tumor B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia
36. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
37. The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma
38. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome
39. Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E
40. Selinexor Enhances NK Cell Activation Against Lymphoma Cells Via Downregulation of HLA-E
41. Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial
42. Targeting Metabolic Alterations in CLL Microenvironment; Inhibition of Glutamine Import Attenuates Venetoclax Resistance
43. Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial
44. Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior
45. The Hydropathy Index of the HCDR3 Region of the B-Cell Receptor Identifies Two Subgroups of IGHV-Mutated Chronic Lymphocytic Leukemia Patients With Distinct Outcome
46. Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia
47. Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia
48. The normal IGHV1-69–derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL
49. Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells
50. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.